Novo Nordisk is pursuing up to $830 million in damages from KBP Biosciences in a Singapore court, alleging that it was misled about the effectiveness of an experimental hypertension drug during a $1.3 billion acquisition. The Danish pharmaceutical company claims that the local biotech company provided false information regarding the drug's potential, prompting Novo Nordisk to seek arbitration in New York. This legal action comes as Novo Nordisk continues to face challenges related to its weight loss drug Ozempic, which has gained popularity but also raised concerns over counterfeit versions and side effects. The company is also involved in broader legal efforts to curb the compounding of GLP-1 products, which it argues could pose risks to public health.